Mr Anthony Wignall

Research Assistant UniSA Clinical & Health Sciences

City West Campus (HB6-18)

email Anthony.Wignall@unisa.edu.au

Research

Research focus

Biological Sciences
Chemical Sciences
Engineering
Medical and Health Sciences
Biomedical Engineering

Research

Outputs

Research outputs for the last seven years are shown below. To see earlier years visit ORCID or Scopus

Open access indicates that an output is open access.

Journal Articles

Year	Output
2023	Awad, M, Kopecki, Z, Barnes, TJ, Wignall, A, Joyce, P, Thomas, N & Prestidge, CA 2023, 'Lipid liquid crystal nanoparticles: promising photosensitizer carriers for the treatment of infected cutaneous wounds', Pharmaceutics, vol. 15, no. 2, pp. 1-18. Open access 64
2023	Subramaniam, S, Joyce, P, Donnellan, L, Young, C, Wignall, A, Hoffmann, P & Prestidge, CA 2023, 'Protein adsorption determines pulmonary cell uptake of lipid-based nanoparticles', Journal of Colloid and Interface Science, vol. 641, pp. 36-47. Open access 4
2023	Wright, L, Wignall, A, Joemetsa, S, Joyce, P & Prestidge, CA 2023, 'A membrane-free microfluidic approach to mucus permeation for efficient differentiation of mucoadhesive and mucopermeating nanoparticulate systems', Drug Delivery and Translational Research, vol.13, no. 4, pp. 1088-1101. 1 6
2022	Joyce, P, Wignall, A, Peressin, K, Wright, L, Williams, DB & Prestidge, CA 2022, 'Chitosan nanoparticles facilitate improved intestinal permeation and oral pharmacokinetics of the mast cell stabiliser cromoglycate', International Journal of Pharmaceutics, vol. 612, article no. 121382. Open access 2 3 3
2022	Secombe, KR, Ball, IA, Wignall, AD, Bateman, E, Keefe, DM & Bowen, JM 2022, 'Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats', Neoplasia, vol. 30, article no. 100806, pp. 1-10. Open access 4 4 1
2022	Tam, JS, Crame, EE, Elz, AS, Coller, JK, Wignall, A, Prestidge, CA & Bowen, JM 2022, 'Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity', Cancer Chemotherapy and Pharmacology, vol. 90, no. 3, pp. 267-278. Open access 1
2022	Thorn, CR, Kopecki, Z, Wignall, A, Kral, A, Prestidge, CA & Thomas, N 2022, 'Liquid crystal nanoparticle platform for increased efficacy of cationic antimicrobials against biofilm infections', Nanomedicine: Nanotechnology Biology and Medicine, vol. 42, article no. 102536. 3 1 1
2022	Thorn, CR, Wignall, A, Kopecki, Z, Kral, A, Prestidge, CA & Thomas, N 2022, 'Liquid crystal nanoparticles enhance tobramycin efficacy in a murine model of Pseudomonas aeruginosa biofilm wound infection', ACS Infectious Diseases, vol. 8, no. 4, pp. 841-854. 2 2 2
2021	Arafat, M, Fouladian, P, Wignall, A, Song, Y, Parikh, A, Albrecht, H, Prestidge, CA, Garg, S & Blencowe, A 2021, 'Development and in vitro evaluation of 5-fluorouracil-eluting stents for the treatment of colorectal cancer and cancer-related obstruction', Pharmaceutics, vol. 13, no. 1, article no. 17, pp. 1-22. Open access 11 9 1
2021	Jia, Z, Wignall, A, Delon, L, Guo, Z, Prestidge, C & Thierry, B 2021, 'An ex vivo model enables systematic investigation of the intestinal absorption and transcytosis of oral particulate nanocarriers', ACS Biomaterial Science and Engineering, online, pp. 1-11. Open access 3 3
2021	Meola, TR, Joyce, P, Wignall, A, Bremmell, KE & Prestidge, CA 2021, 'Harnessing the potential of nanostructured formulations to mimic the food effect of lurasidone', International Journal of Pharmaceutics, vol. 608, article no. 121098, pp. 1-10. Open access 3 3 4
2021	Secombe, KR, Ball, IA, Shirren, J, Wignall, AD, Keefe, DM & Bowen, JM 2021, 'Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant', Breast Cancer, vol. 28, no. 1, pp. 99-109. 4 3 3
2020	Joyce, P, Dening, TJ, Meola, TR, Wignall, A, Ulmefors, H, Kovalainen, M & Prestidge, CA 2020, 'Contrasting anti-obesity effects of smectite clays and mesoporous silica in sprague-dawley rats', ACS Applied Bio Materials, vol. 3, no. 11, pp. 7779-7788. 3 3
2020	Joyce, P, Ulmefors, H, Maghrebi, S, Subramaniam, S, Wignall, A, Jõemetsa, S, Höök, F & Prestige, CA 2020, 'Enhancing the cellular uptake and antibacterial activity of rifampicin through encapsulation in mesoporous silica nanoparticles', Nanomaterials, vol.4, no.4, pp. 1-16. Open access 19 20
2020	Mayo, BJ, Secombe, KR, Wignall, AD, Bateman, E, Thorpe, D, Pietra, C, Keefe, DM & Bowen, JM 2020, 'The GLP-2 analogue elsiglutide reduces diarrhoea caused by the tyrosine kinase inhibitor lapatinib in rats', Cancer Chemotherapy and Pharmacology, vol. 85, pp. 793-803. 13 12 5
2019	Secombe, KR, Ball, IA, Shirren, J, Wignall, AD, Finnie, J, Keefe, D, Avogadri-Connors, F, Olek, E, Martin, D, Moran, S & Bowen, JM 2019, 'Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model', Cancer Chemotherapy and Pharmacology, vol. 83, no. 3, pp. 531-543. 11 8
2019	Tam, SYJ, Coller, JK, Wignall, A, Gibson, RJ, Khatri, A, Barbé, C & Bowen, JM 2019, 'Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis', Annals of Gastroenterology, vol. 32, no. 6, pp. 584-592. Open access 4 3
2018	Stansborough, RL, Bateman, EH, Al-Dasooqi, N, Bowen, JM, Wignall, A, Keefe, DM, Yeoh, AS, Logan, RM, Yeoh, EE, Stringer, AM & Gibson, RJ 2018, 'Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity', International Journal of Radiation Biology, vol. 94, no. 7, pp. 645-655. Open access 6 4
2017	Coller, JK, Bowen, JM, Ball, IA, Wardill, HR, Van Sebille, YZ, Stansborough, RL, Lightwala, Z, Wignall, A, Shirren, J, Secombe, K & Gibson, RJ 2017, 'Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report', Cancer Chemotherapy and Pharmacology, vol. 79, no. 2, pp. 431-434. 8 7
2016	Bateman, E, Weaver, E, Klein, G, Wignall, A, Wozniak, B, Plews, E, Mayo, B, White, I & Keefe, D 2016, 'Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis', Supportive Care in Cancer, vol. 24, no. 1, pp. 377-385. Open access 3 8 1
2014	Bowen, JM, Mayo, BJ, Plews, E, Bateman, E, Wignall, A, Stringer, AM, Boyle, FM & Keefe, DM 2014, 'Determining the mechanisms of lapatinib-induced diarrhoea using a rat model', Cancer Chemotherapy and Pharmacology, vol. 74, no. 3, pp. 617-627. 5 16 3
2013	Bateman, E, Bowen, J, Stringer, A, Mayo, B, Plews, E, Wignall, A, Greenberg, N, Schiffrin, E & Keefe, D 2013, 'Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model', Nutrients, vol. 5, no. 10, pp. 3948-3963. Open access 9 9 1

External engagement & recognition

Collaborations

External engagement & recognition

Collaborations

Organisation	Country
Ceramisphere	AUSTRALIA
Chalmers University of Technology	SWEDEN
Entera Health Inc.	UNITED STATES
Helsinn Healthcare S.A.	AUSTRALIA
Nestle Nutrition R & D Center	UNITED STATES
Nestle Research centre	SWITZERLAND
Oulun Yliopisto	FINLAND
Puma Biotechnology (United States)	UNITED STATES
Royal Adelaide Hospital	AUSTRALIA
SA Pathology	AUSTRALIA
University of Adelaide	AUSTRALIA
University of South Australia	AUSTRALIA
University of Sydney	AUSTRALIA

more less

Mr Anthony Wignall

About me

About me

UniSA Clinical & Health Sciences

About me

Professional Associations

Experience

Qualifications

Research

Research focus

Projects

Outputs

Journal Articles

External engagement & recognition

Collaborations

Collaborations

Gallery